Roth Comments on Ligand Pharma (LGND) Following EU Marketing Authorization of Duavive
Tweet Send to a Friend
Roth Capital affirms Ligand Pharmaceuticals (Nasdaq: LGND) at Buy with a price target of $116 following news that the pharma's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
